Target FAPClass Small molecule (quinoline inhibitor, DOTA chelator)
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.
| Form | Use | Molar mass (labelled form) | Ongoing trials | Most advanced phase | Approval |
|---|---|---|---|---|---|
| [⁶⁸Ga]Ga-FAPI-46 Syntheses and QC ↗ | Imaging | — | 44 | Phase 3 | — |
| [¹⁷⁷Lu]Lu-FAPI-46 Syntheses and QC ↗ | Therapy | — | 0 | — | — |
Atlas trials whose studied drug or title names this vector, with this radionuclide.
| Trial | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
| FAP ligands (FAPI)2023-506030-70-00 · Pancreas (adenocarcinoma) | Phase 3 | Not yet recruiting | Universitaetsklinikum Essen AöR | 1 |
| FAP ligands (FAPI)2024-516486-36-00 · Pancreas (adenocarcinoma) | Phase 3 | Recruiting | Stichting Amsterdam UMC | 1 |
| FAP ligands (FAPI)2024-517931-29-00 · Inflammatory diseases | Phase 3 | Recruiting | Universitair Medisch Centrum Groningen | 1 |
| FAP ligands (FAPI)2025-520731-17-02 · Other | Phase 3 | Not yet recruiting | Centre Hospitalier Regional Et Universitaire De Brest | 1 |
| FAP ligands (FAPI)2024-517257-27-00 · Other | Phase 3 | Recruiting | Universitair Medisch Centrum Groningen | 1 |
| FAP ligands (FAPI)NCT05518903 · Pancreas (adenocarcinoma) | Phase 2 | Recruiting | Mayo Clinic | 1 |
| BEFAST · FAP ligands (FAPI)NCT07629609 · Pancreas (adenocarcinoma) | Phase 2 | Recruiting | Barbara Malene Fischer | 1 |
| FAP ligands (FAPI)2024-518765-96-00 · Solid tumors (multiple indications) | Phase 2 | Recruiting | Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico | 1 |
| FAPI-PM · FAP ligands (FAPI)NCT06790082 · Solid tumors (multiple indications) | Phase 2 | Recruiting | Aalborg University Hospital | 1 |
| FAP ligands (FAPI)NCT06335069 · Breast | Phase 2 | Recruiting | Maastricht University Medical Center | 1 |
| FAP ligands (FAPI)2024-511659-17-00 · Solid tumors (multiple indications) | Phase 2 | Recruiting | Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. | 1 |
| FAP ligands (FAPI)2024-514504-13-00 · Inflammatory diseases | Phase 2 | Recruiting | MoonLake Immunotherapeutics AG | 1 |
| FAPDIG · FAP ligands (FAPI)NCT07478523 · Pancreas (adenocarcinoma) | Phase 2 | Recruiting | University Hospital, Bordeaux | 1 |
| FAPICAM · FAP ligands (FAPI)NCT07549841 · Cardiac amyloidosis | Phase 2 | Recruiting | Nantes University Hospital | 1 |
| FAPIHN · FAP ligands (FAPI)NCT06794372 · Head and neck | Phase 2 | Recruiting | John O. Prior | 1 |
| BEFAST · FAP ligands (FAPI)NCT07215182 · Melanoma | Phase 2 | Recruiting | Barbara Malene Fischer | 1 |
| FAP ligands (FAPI)2025-524874-41-00 · Sarcoma / bone | Phase 2 | Not yet recruiting | Rigshospitalet | 1 |
| FAP ligands (FAPI)2024-511977-31-01 · Atherosclerosis and vessels | Phase 2 | Not yet recruiting | Universitair Medisch Centrum Groningen | 1 |
| MI-CISDIR · FAP ligands (FAPI)NCT06540872 · Breast | Phase 2 | Recruiting | Universität Münster | 1 |
| INDIGO-FAPI · FAP ligands (FAPI)NCT06659705 · Pancreas (adenocarcinoma) | Phase 2 | Recruiting | Institut Curie | 1 |
| FAP ligands (FAPI)2025-524897-40-00 · Breast | Phase 2 | Not yet recruiting | Hospices Civils De Lyon | 1 |
| FAP ligands (FAPI)2025-524434-25-00 · Stomach / esophagus | Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire De Bordeaux | 1 |
| FAP ligands (FAPI)2025-521163-12-01 · Thyroid | Phase 2 | Not yet recruiting | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | 1 |
| FAP ligands (FAPI)2025-523032-39-00 · Small-cell lung cancer | Phase 2 | Not yet recruiting | Academisch Ziekenhuis Maastricht | 1 |
| FAP ligands (FAPI)NCT05172310 · Pancreas (adenocarcinoma) | Phase 1 | Recruiting | Karolinska University Hospital | 1 |
| FAP ligands (FAPI)2023-506594-35-00 · Colorectal | Phase 1 | Recruiting | Amsterdam UMC | 1 |
| FAP ligands (FAPI)2024-518838-82-00 · Inflammatory diseases | Phase 1 | Recruiting | Universitair Medisch Centrum Groningen | 1 |
| FAPI-PETCD · FAP ligands (FAPI)NCT07273188 · Inflammatory diseases | Phase 1 | Recruiting | Mayo Clinic | 1 |
| FAPI PET Prost · FAP ligands (FAPI)NCT04457232 · Prostate – other | Phase 1 | Active, not recruiting | Jonsson Comprehensive Cancer Center | 1 |
| FAPI ILD · FAP ligands (FAPI)NCT05365802 · Inflammatory diseases | Phase 1 | Active, not recruiting | University of California, Los Angeles | 1 |
| FAP ligands (FAPI)NCT07118176 · Prostate – other | Phase 1 | Active, not recruiting | Jonsson Comprehensive Cancer Center | 1 |
| FAP ligands (FAPI)NCT07817563 · Non-small-cell lung cancer | Phase 1 | Not yet recruiting | Mayo Clinic | 1 |
| FAPI PET RDRC · FAP ligands (FAPI)NCT04459273 · NETs and neuroendocrine carcinomas (other) | Phase 1 | Active, not recruiting | Jonsson Comprehensive Cancer Center | 1 |
| FAP ligands (FAPI)NCT04457258 · Sarcoma / bone | Phase 1 | Active, not recruiting | Jonsson Comprehensive Cancer Center | 1 |
| CUPCAKE · FAP ligands (FAPI)NCT06225505 · Breast | No phase | Recruiting | Institut Curie | 1 |
| PARADISE · FAP ligands (FAPI)NCT06275477 · Inflammatory diseases | No phase | Recruiting | University Hospital, Brest | 1 |
| FAP ligands (FAPI)NCT06232122 · Gynecological | No phase | Recruiting | Chang Gung Memorial Hospital | 1 |
| Ga-68-FAPI-46 · FAP ligands (FAPI)NCT06769828 · Colorectal | No phase | Recruiting | Koo Foundation Sun Yat-Sen Cancer Center | 1 |
| FAP ligands (FAPI)NCT06911021 · Pancreas (adenocarcinoma) | No phase | Not yet recruiting | Centre Hospitalier Universitaire Vaudois | 1 |
| FAPeCa · FAP ligands (FAPI)NCT06061874 · Solid tumors (multiple indications) | No phase | Recruiting | Jules Bordet Institute | 1 |
| INTERACT-FAPI · FAP ligands (FAPI)NCT06957782 · Other | No phase | Not yet recruiting | Erasmus Medical Center | 0 |
| FAP-IT · FAP ligands (FAPI)NCT06349512 · Breast | No phase | Recruiting | Institut Curie | 1 |
| FAPI-PET · FAP ligands (FAPI)NCT06790264 · Breast | No phase | Recruiting | European Institute of Oncology | 1 |
| GALILEE · FAP ligands (FAPI)NCT05931302 · Breast | No phase | Active, not recruiting | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | 1 |
| Folate receptor tracers2024-513537-21-02 · Inflammatory diseases | Phase 2 | Recruiting | Amsterdam UMC Stichting | 1 |
| [68Ga]Ga-PSMA-11NCT04147494 · Prostate – other | Phase 1 | Active, not recruiting | Jonsson Comprehensive Cancer Center | 1 |
| 2026-08 | FAPeCa · positiveIn 61 patients with colorectal or ovarian peritoneal carcinomatosis, FAPI PET agrees best with surgical staging (ICC 0.81 vs 0.76 for MRI and 0.54 for FDG). More sensitive but less specific; performance maintained after chemotherapy. | J Nucl Med ↗ |
341 publications in PubMed for the query below; the most recent:
"FAPI-46"[tiab] OR "FAPI46"[tiab]
Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
FAPI-46. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/fapi-46/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.